The Covid ef­fect has trig­gered some rad­i­cal changes to the top 50 bio­phar­ma list, bring­ing a whole new group of play­ers in­to the big league

Last year
Pharma

Francesco De Ru­ber­tis makes his lega­cy play, re­cruit­ing star ex­ecs and rolling up 10 biotech star­tups in­to a $250M gam­ble on cre­at­ing some­thing new in phar­ma

Last year
Startups

SR One re­cruits an IPO vet and sea­soned ops chief for the ven­ture team. And they have some prac­ti­cal ad­vice for you

Last year
People

The SPAC at­tack has just be­gun. And the Richard Bran­son deal is just the tip of the biotech ice­berg

Last year
Financing

The in­side sto­ry be­hind the fall of Lau­rie Glim­cher's big I/O start­up and the of­ten tense equa­tion of sci­ence and mon­ey

Last year
Startups

Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is push­ing every­body in­to this sec­tor'

Last year
Deals

Ex­clu­sive: Third Rock­'s stealthy MO­MA Ther­a­peu­tics taps a long­time Mil­len­ni­um, Take­da vet as CEO

Last year
People

Is it time to stock up on wine? This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions

Last year
Bioregnum
Opinion

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

Last year
Bioregnum
Opinion

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Last year
In Focus

Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

Last year
People

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the biotech scene

Last year
Bioregnum
Opinion

Al­bireo just ad­vanced down to the 10-yard line at the FDA. And Ron Coop­er’s team is get­ting prepped for the next big play

Last year
FDA+

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

Last year
R&D

As coro­n­avirus vari­ants trig­ger new alarms, the NIH is putting an un­der-the-radar ‘next-gen’ vac­cine in­to PhI

Last year
Discovery

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

Last year
Bioregnum
Opinion

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it to the clin­ic

Last year
Financing

With a tor­rent of ven­ture cash gush­ing from a glob­al pack of uni­corn hunters, this biotech founder vows to stay hun­gry

Last year
Financing

A vet­er­an on­col­o­gy start­up crew is mak­ing a very se­ri­ous bet that they’ve found the key to un­lock­ing the promise of on­colyt­ic virus­es

Last year
Financing
Startups

It was the best of all pos­si­ble worlds in the worst of all times for biotech in 2020. What comes now?

Last year
Financing

John Con­nol­ly has a new mis­sion to tack on to his role at the Park­er In­sti­tute: in­ter­im chief of a buzzy biotech backed by a pair of bil­lion­aires

Last year
Bioregnum
Opinion

Backed by a $200M in­vest­ment from a Ko­re­an con­glom­er­ate, Vivek Ra­maswamy has qui­et­ly built a ‘moth­er ship’ for vant cre­ation — with a whole new strat­e­gy in mind

Last year
Deals

The FDA spells out 4 rea­sons why it hates Min­er­va’s NDA ideas — but the biotech is go­ing for it any­way

Last year
FDA+

Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

Last year
Bioregnum
R&D
First page Previous page 6789101112 Next page Last page